Conatumumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Conatumumab
Monoclonal antibody
Type Whole antibody
Source Human
Target TRAIL-R2 (CD262)
Clinical data
ATC code
  • none
Identifiers
Synonyms anti-TRAIL receptor 2 monoclonal antibody, AMG-655
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Formula C6466H10006N1730O2024S40
Molar mass 145.65 kg/mol
 NYesY (what is this?)  (verify)

Conatumumab (originally AMG-655) is a monoclonal antibody developed for the treatment of cancer. It is a fully human monoclonal agonist antibody directed against the extracellular domain of human TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor 2 (TR-2, death receptor 5) with potential antineoplastic activity. Conatumumab mimics the activity of native TRAIL, binding to and activating TR-2, thereby activating caspase cascades and inducing tumor cell apoptosis. TR-2 is expressed by a variety of solid tumors and cancers of hematopoietic origin.[1][2]

The drug was developed by Amgen Inc. In 2008, Takeda licensed the drug from Amgen for development in Japan, but discontinued development in 2011.

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council – Conatumumab, American Medical Association.
  2. ^ National Cancer Institute: Definition of conatumomab